NCT00310596 - Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

March 31, 2004

Conditions

Healthy

Interventions

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

0,1mmol/kg at 10 mL/15 sec

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

same dose as arm 1 at bolus rate (2mL/sec)

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

0,3mmol/kg at 10 mL/15 sec

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

same dose as arm 3 at bolus rate (2mL/sec)

DRUG

Moxifloxacin (BAY12-8039)

400 mg at 0,07 mL/sec over 60 min

DRUG

Placebo

0,9% saline at 0,6mL/kg at bolus rate

Trial Locations (1)

Miami